These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 16869344)

  • 1. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases.
    Scheiman JM
    Drugs; 2006; 66 Suppl 1():15-21; discussion 29-33. PubMed ID: 16869344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
    Johnell K; Fastbom J
    Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin.
    Chan FK
    Drugs; 2006; 66 Suppl 1():23-8; discussion 29-33. PubMed ID: 16869345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    Borer JS; Simon LS
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Strand V
    Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to advise aspirin use in patients who need NSAIDs.
    Sopena F; Lanas A
    Curr Pharm Des; 2007; 13(22):2248-60. PubMed ID: 17691998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.
    Scheiman JM; Fendrick AM
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S23-9. PubMed ID: 16168078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ; Benraad HB; Rasker JJ
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for gastrointestinal bleeding associated with low-dose aspirin.
    Valkhoff VE; Sturkenboom MC; Kuipers EJ
    Best Pract Res Clin Gastroenterol; 2012 Apr; 26(2):125-40. PubMed ID: 22542151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drugs versus selective COX-2 inhibitors in the upper gastrointestinal tract.
    Schölmerich J
    J Cardiovasc Pharmacol; 2006; 47 Suppl 1():S67-71. PubMed ID: 16785832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1240-8. PubMed ID: 20955443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.
    Lanas A; Scheiman J
    Curr Med Res Opin; 2007 Jan; 23(1):163-73. PubMed ID: 17257477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden.
    Brusselaers N; Lagergren J
    BMJ Open; 2018 Jul; 8(7):e021869. PubMed ID: 29982219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.